Terms: = Liver cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Treatment
310 results:
1. A case study of a liver transplant-treated patient with glycogen storage disease type Ia presenting with multiple inflammatory hepatic adenomas: an analysis of clinicopathologic and genetic data.
Wang A; Wu J; Yuan X; Liu J; Lu C
BMC Med Genomics; 2024 May; 17(1):124. PubMed ID: 38711024
[TBL] [Abstract] [Full Text] [Related]
2. Intestinal microbiota and biliary system diseases.
Wang H; Gong J; Chen J; Zhang W; Sun Y; Sun D
Front Cell Infect Microbiol; 2024; 14():1362933. PubMed ID: 38558851
[TBL] [Abstract] [Full Text] [Related]
3. [Surgical treatment and prognosis analysis of hilar cholangiocarcinoma].
Li XC; Li CX; Zhang H; Cheng F; Zhang F; Pu LY; Zhang CY; Wang K; Kong LB; Qian XF; Li DH; Lu WX; Wang P; Yao AH; Bai JF; Wu XF; Chen RX; Wang XH
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):290-301. PubMed ID: 38432670
[No Abstract] [Full Text] [Related]
4. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
[TBL] [Abstract] [Full Text] [Related]
5. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract] [Full Text] [Related]
6. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
7. Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study.
Fang C; Xu C; Jia X; Li X; Yin C; Xing X; Li W; Wang Z
BMC Gastroenterol; 2024 Jan; 24(1):1. PubMed ID: 38166611
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the efficacy and safety of CalliSpheres® microsphere-transarterial chemoembolization in large hepatocellular carcinoma.
Zhou C; Peng C; Liu F; Xiao J; Li G; Chen C; Shi L; Li H
J Cancer Res Ther; 2023 Dec; 19(6):1575-1581. PubMed ID: 38156924
[TBL] [Abstract] [Full Text] [Related]
9. [Burden of hepatitis B-associated diseases in China from 1990 to 2030].
Yao L; Lin S; Huang J; Wu Y
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2023 Nov; 35(5):464-475. PubMed ID: 38148535
[TBL] [Abstract] [Full Text] [Related]
10. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
11. Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Yokohama K; Nishikawa H; Nishimura T; Shimada N; Kawata K; Kosaka H; Naganuma A; Yata Y; Ohama H; Kuroda H; Tanaka K; Tanaka T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M; Kumada T;
Cancer Med; 2023 Dec; 12(24):21680-21693. PubMed ID: 37987139
[TBL] [Abstract] [Full Text] [Related]
12. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
13. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
[TBL] [Abstract] [Full Text] [Related]
14. Tislelizumab vs Sorafenib as First-Line treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.
Qin S; Kudo M; Meyer T; Bai Y; Guo Y; Meng Z; Satoh T; Marino D; Assenat E; Li S; Chen Y; Boisserie F; Abdrashitov R; Finn RS; Vogel A; Zhu AX
JAMA Oncol; 2023 Dec; 9(12):1651-1659. PubMed ID: 37796513
[TBL] [Abstract] [Full Text] [Related]
15. Metastatic pituitary tumors: an institutional case series.
Yearley AG; Chalif EJ; Gupta S; Chalif JI; Bernstock JD; Nawabi N; Arnaout O; Smith TR; Reardon DA; Laws ER
Pituitary; 2023 Oct; 26(5):561-572. PubMed ID: 37523025
[TBL] [Abstract] [Full Text] [Related]
16. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.
Chavda V; Zajac KK; Gunn JL; Balar P; Khadela A; Vaghela D; Soni S; Ashby CR; Tiwari AK
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1821. PubMed ID: 37344125
[TBL] [Abstract] [Full Text] [Related]
17. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract] [Full Text] [Related]
18. Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
Shao M; Tao Q; Xu Y; Xu Q; Shu Y; Chen Y; Shen J; Zhou Y; Wu Z; Chen M; Yang J; Shi Y; Wen T; Bu H
Chin Med J (Engl); 2023 Sep; 136(17):2066-2076. PubMed ID: 37249521
[TBL] [Abstract] [Full Text] [Related]
19. Thermal-/pH-triggered hollow mesoporous carbon nanocarrier for NIR-responsive drug release.
Lin YS; Lin KS; Mdlovu NV; Kung PY; Jeng US
Biomater Adv; 2023 Aug; 151():213477. PubMed ID: 37244029
[TBL] [Abstract] [Full Text] [Related]
20. Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
Kim KA; Choi HY; Ki M; Jang ES; Jeong SH
J Gastroenterol; 2023 Jul; 58(7):682-692. PubMed ID: 37195516
[TBL] [Abstract] [Full Text] [Related]
[Next]
